Modified Apolipoprotein Nanoparticles for Macrophage Targeted Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging techniques for cancer and atherosclerosis, such as MRI, face challenges in achieving targeted and specific delivery of contrast agents to tumor-associated macrophages and atherosclerotic plaques, leading to low efficacy and potential systemic toxicity due to high doses required for imaging.
Innovation Solution
Development of nanoparticles comprising chemically or enzymatically modified apolipoproteins, specifically apolipoproteins A-I and A-II, combined with metallic or non-metallic contrast agents, which are designed to target macrophages through scavenger receptors, allowing for enhanced uptake and reduced systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If high doses of contrast agents are administered to achieve sufficient imaging signal, then imaging efficacy is improved, but systemic toxicity increases
Solution Approach 1:
The contrast agent system is segmented into two functional components: a targeting moiety (modified apolipoprotein) that directs the agent to specific cells, and a contrast agent component that provides the imaging signal. This segmentation allows the contrast agent to be delivered precisely to target cells, improving imaging efficacy at lower doses and reducing systemic toxicity.
Solution Approach 2:
Modified apolipoproteins serve as intermediary molecules that mediate between the contrast agent and target cells. These intermediaries bind to scavenger receptors on macrophages, facilitating selective uptake of the contrast agent into target cells while minimizing exposure to non-target tissues, thereby reducing systemic toxicity.
2Ease of operation
If conventional contrast agents are used without targeted delivery, then ease of administration is maintained, but delivery efficiency to target cells is low
Solution Approach 1:
The modified apolipoprotein-conjugated contrast agents utilize the body's own cellular uptake mechanisms (scavenger receptor-mediated endocytosis) for targeted delivery. The targeting moiety naturally binds to and is internalized by macrophages through existing physiological pathways, enabling self-directed delivery to target cells without requiring complex external delivery systems.
3Device complexity
If non-targeted contrast agents are administered, then device complexity is low, but targeting selectivity is poor
Solution Approach 1:
The contrast agent is constructed as a composite material combining a modified apolipoprotein (targeting moiety) with a contrast agent molecule. This composite structure integrates the targeting functionality of the protein with the imaging functionality of the contrast agent, achieving both targeting selectivity and imaging capability in a single agent formulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified nanoparticle compositions enable targeted delivery of contrast agents to macrophages, improving imaging efficacy while reducing the required dose and associated systemic toxicity, thus enhancing the quality and safety of imaging procedures.
Implementation Method 1
The invention provides various nanoparticles that contain chemically and/or enzymatically modified apolipoproteins and are used for the delivery of an imaging contrast agent
Data Source
AI summary
A new approach to targeting imaging agents to macrophage-rich sites of interest is disclosed. Compositions of the invention are rHDL and HDL-like liposomal compositions, protein constituents of which, apolipoproteins A-I and/or A-II or fragments thereof are used not only as structural but also as targeting agents. This is achieved by certain controlled chemical or enzymatic modification of apolipoproteins A-I or A-II or fragments thereof. Such modification converts these apolipoproteins to substrates for macrophage scavenger receptors and results in the improvement of contrast agent-(HDL/modified apolipoprotein)-particle association with macrophages and/or absorption (uptake) by macrophages when compared to that of the contrast agent-(HDL/apolipoprotein)-particle constructed with non-modified naturally occurring apo A-I. The compositions can be used for noninvasive specific in vivo molecular detection and localization of macrophage-rich sites of interest using imaging techniques such as computed tomography (CT), gamma-scintigraphy, positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI).